IP Library › Assignment 037601/0048
Patent Assignment
Reel/Frame 037601/0048

Assignment of Assignor's Interest

Recorded: 2016-01-27 Pages: 16
Assignor
BAVARIAN NORDIC INC.
Executed: 2016-01-01
Assignee
BAVARIAN NORDIC A/S
HEJRESKOVVEJ 10A, KVISTGAARD, DK-3490, DENMARK
Covered Properties (16)
Use of Mva to Treat Prostate Cancer
Combination Therapy for Treating Cancer with a Recombinant Poxvirus Expressing a Tumor Antigen and an Immune Checkpoint Molecule Antagonist or Agonist
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of Tim-3
Methods for Therapeutic Vaccination
Patent: 7,005,498 →
Application: 09/806,703 →
Novel Methods for Therapeutic Vaccination
Patent: 7,820,633 →
Application: 10/441,779 →
Publication: US 2004/0141958
Purification of Her-2 Variants
Patent: 7,763,452 →
Application: 10/560,961 →
Publication: US 2006/0240511
Novel Methods for Therapeutic Vaccination
Patent: 7,807,441 →
Application: 11/202,516 →
Publication: US 2006/0008465
Methods for Treating Cancer with a Recombinant Mva Expressisng Her-2
Patent: 7,807,146 →
Application: 11/905,876 →
Publication: US 2008/0213302
Use of Mva to Treat Prostate Cancer
Patent: 7,867,483 →
Application: 12/253,094 →
Publication: US 2009/0104225
Immunogenic Her-2 Variants
Patent: 8,022,039 →
Application: 12/824,420 →
Publication: US 2010/0285071
Use of Mva to Treat Prostate Cancer
Patent: 8,377,688 →
Application: 12/871,017 →
Publication: US 2011/0008386
Methods for Treating Cancer with a Recombinant Mva Expressing Her-2
Patent: 8,313,740 →
Application: 12/872,156 →
Publication: US 2011/0008294
Methods and Compositions for the Treatment of Cancer
Application: 14/435,891 →
Publication: US 2015/0283220
Compositions and Methods for the Treatment of Cancer
Application: 61/716,181 →
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of Tim-3
Application: 61/992,771 →
Combination Therapy for Treating Cancer with a Recombinant Poxvirus Expressing a Tumor Antigen and an Immune Checkpoint Molecule Antagonist or Agonist
Application: 61/992,788 →
Related Assignments (13)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 30, 2001
From: STEINAA, LUCILLA; MOURITSEN, SOREN; GAUTAM, ANAND; DALUM, IBEN
To: M & E BIOTECH A/S
Reel/Frame 011761/0986 →
Change of Name Feb 3, 2004
From: M&E BIOTECH A/S
To: PHARMEXA A/S
Reel/Frame 014301/0197 →
Assignment of Assignor's Interest May 30, 2006
From: ESKLING, MARIE; NIELSEN, KLAUS GREGORIUS
To: PHARMEXA A/S
Reel/Frame 017693/0514 →
Assignment of Assignor's Interest Feb 6, 2008
From: DELCAYRE, ALAIN; LAUS, REINER; MANDL, STEFANIE
To: BN IMMUNOTHERAPEUTICS INC.
Reel/Frame 020466/0061 →
Assignment of Assignor's Interest Nov 3, 2008
From: DELCAYRE, ALAIN; LAUS, REINER; MANDL, STEFANIE; ROUNTREE, RYAN BLAIR
To: BN IMMUNOTHERAPEUTICS INC.
Reel/Frame 021777/0671 →
Assignment of Assignor's Interest Feb 26, 2009
From: PHARMEXA A/S
To: BN IMMUNOTHERAPEUTICS, INC.
Reel/Frame 022318/0984 →
Assignment of Assignor's Interest Feb 26, 2009
From: PHARMEXA A/S
To: BN IMMUNOTHERAPEUTICS, INC.
Reel/Frame 022309/0985 →
Assignment of Assignor's Interest Feb 26, 2009
From: PHARMEXA A/S
To: BN IMMUNOTHERAPEUTICS, INC.
Reel/Frame 022319/0010 →
Assignment of Assignor's Interest Feb 26, 2009
From: PHARMEXA A/S
To: BN IMMUNOTHERAPEUTICS, INC.
Reel/Frame 022319/0031 →
Change of Name Aug 7, 2013
From: BN IMMUNOTHERAPEUTICS, INC.
To: BAVARIAN NORDIC, INC.
Reel/Frame 030965/0065 →
Assignment of Assignor's Interest Jun 6, 2014
From: FOY, SUSAN; MANDL, STEFANIE; ROUNTREE, RYAN; FRANZUSOFF, ALEX
To: BAVARIAN NORDIC, INC.
Reel/Frame 033047/0439 →
Assignment of Assignor's Interest Jun 6, 2014
From: FOY, SUSAN; MANDL, STEFANIE; ROUNTREE, RYAN
To: BAVARIAN NORDIC, INC.
Reel/Frame 033047/0267 →
Assignment of Assignor's Interest Jul 22, 2014
From: DELCAYRE, ALAIN; MANDL, STEFANIE; ROUNTREE, RYAN
To: BAVARIAN NORDIC, INC.
Reel/Frame 033367/0205 →